CDKN1B and breast carcinoma: Increased tamoxifen resistance in breast cancer is associated with the inhibition of p27 regulated by elevating the expression of miR-221/222, and overexpression of p27 in the resistant cells can enhance their sensitivity to tamoxifen (64).